Buspirone: Future directions

Journal of Clinical Psychopharmacology

Volumn 19, Issue 1, 1999, Pages 86-93

  Apter, Jeffrey T ^a   Allen, Lesley A ^b  

^a Princeton Biomedical Research   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE;

ANXIETY NEUROSIS; BEHAVIOR DISORDER; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BEHAVIORAL SYMPTOMS; BUSPIRONE; FORECASTING; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032910454     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199902000-00014     Document Type: Review

References (73)

1. Tompkins EC, Clemento AJ, Taylor DP, Perhach JL. Inhibition of aggressive behavior in rhesus monkeys by buspirone. Res Commun Psychol Psychiatry Behav 1980;5:337-52.
2. Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979;136:1184-7.
3. Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, Danton J. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982;43:81-6.
4. Schweizer E, Rickels K. New and emerging clinical uses for buspirone. J Clin Psychiatry Monograph 1994;12:46-54.
5. Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry Monograph 1994;12:3-19.
6. Goa KL, Ward A. Buspirone a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986;32:114-29.
7. Robinson DS, Rickels K, Feighner J, Fabre LF, Gammans RE, Shrotriya RC, Alms DR, Andary JJ, Messina ME. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10[suppl 3]:67S-76S.
8. Pecknold JC. Serotonin 5-HT1A agonists: a comprehensive review. CNS Drugs 1994;2:234-51.
9. Tunnieliff G. Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol 1991;69:149-56.
10. Peroutka SJ. 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci 1988;11:496-500.
11. Pohl R, Balon R, Yeragani VK, Gershon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 1989;22[suppl 1]:60-7.
12. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993;88:1-11.
13. Griffith JD, Jasinski DR, Casten GP, McKinney GR. Investigation of the abuse liability of buspirone in alcohol-dependent patients Am J Med 1986;80:30-5.
14. Lader M. Assessing, the potential for buspirone dependence or abuse and effects of its withdrawal. Am J Med 1987;82:20-6.
15. Erwin CW, Linnoila M, Hartwell J, Erwin A, Guthrie S. Effects of buspirone and diazepam alone and in combination with alcohol, on skilled performance and evoked potentials. J Clin Psychopharmacol 1986;6:199-209.
16. Mattila MJ, Aranko K, Seppala T. Acute effects of buspirone and alcohol on psychomotor skills. J Clin Psychiatry 1982;43:56-61.
17. Moskowitz H, Smiley A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry 1982;43:45-55.
18. Riblet LA, Taylor DP, Eison MS, Stanton HC. Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 1982;43:11-8.
19. Riblet LA, Eison AS, Eison MS, Taylor DP, Temple DL. Neuropharmacology of buspirone. Psychopathology 1984;17[suppl 3]:69-78.
20. Seppala T, Aranko K, Mattila MJ, Shrotriya RC. Effects of alcohol on buspirone and lorazepam actions. Clin Pharmacol Ther 1982; 32:201-7.
21. Dimitriou EC. Augmenting the effects of antidepressant medication by adding buspirone. Presented at the Tenth World Congress of Psychiatry, Madrid, Spain, August 23, 1996.
22. Robillard M, Lieff S. Augmentation of antidepressant therapy by buspirone: three geriatric case histories [letter]. Can J Psychiatry 1995;40:639-40.
23. Lebert R, Pasquier F, Goudemand M, Petit H. Euphoria with buspirone after fluoxetine treatment [letter]. Am J Psychiatry 1993; 150:167.
24. Stanley MA, Turner SM. Current status of pharmacological and behavioral treatment of obsessive-compulsive disorder. Behav Ther 1995;26:163-86.
25. Pato MT, Pigott TA, Hill JL, Grover GN, Bernstein S, Murphy DL. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991;148:127-9.
26. Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry 1991;52:13-4.
27. Markowitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1990;147:798-800.
28. Jenike MA, Baer L. An open trial of buspirone in obsessive-compulsive disorder. Am J Psychiatry 1988;145:1285-6.
29. Pigott TA, L'Heureux F, Hill JL, Biharik K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:11-8.
30. Grady TA, Pigott TA, L'Heureux F, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone hydrochloride for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993;150:819-21.
31. Menkes DB. Buspirone augmentation of sertraline [letter]. Br J Psychiatry 1995;166:823-4.
32. Veivia AJ, Levin GM, Powell HS. Buspirone and sertraline in the treatment of a patient with refractory obsessive-compulsive disorder. J Pharm Technol 1995;11:50-2.
33. McDougle CJ, Goodman WK, Leckman JF. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1993;150:647-9.
34. Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH. Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 1993;54[suppl 6]:16-6.
35. Hollander E, Liebowitz MR, Winchel R, Klumer A, Klein DF. Treatment of body-dysmorphic disorder with serotonin reuptake blockers. Am J Psychiatry 1989;146:768-70.
36. Phillips KA, McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JL. Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry 1993;150:302-8.
37. Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull 1996;32:175-80.
38. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
39. Tancer ME, Uhde TW. Social phobia: a review of pharmacological treatment. CNS Drugs 1995;3:267-78.
40. van Vliet IM, den Boer JA, Westenberg HGM, Ho Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997;58:164-8.
41. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996;39:115-21.
42. Davidson J. Drug therapy of post-traumatic stress disorder. Br J Psychiatry 1992;160:309-14.
43. Fichtner CG, Crayton JW. Buspirone in combat-related post traumatic stress disorder [letter]. J Clin Psychopharmacol 1994;14: 79-80.
44. Norden MJ. Buspirone treatment of sexual dsyfunction associated with selective serotonin re-uptake inhibitors. Depression 1994;2:109-12.
45. Ellison JM, Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 1993;54:432-4.
46. Romanelli F, Adler DA, Bungay KM. Possible paroxetine-induced bruxism. Ann Pharmacother 1996;30:1246-7.
47. Geller I, Hartmann RJ. Effects of buspirone on operant behavior of laboratory rats and cynomolgus monkeys. J Clin Psychiatry 1982;43:25-33.
48. Stein DJ, Hollander E, Liebowitz MR. Neurobiology of impulsivity and the impulse control disorders. J Neuropsychiatry Clin Neurosci 1993;5:9-17.
49. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987;48[suppl 5]:9-15.
50. Rovner B, Kafonek S, Filipp L, Lucas MJ, Flostein MF. Prevalence of mental illness in a community nursing home. Am J Psychiatry 1986;143:1446-9.
51. Tariot PN, Podgorski CA, Blazina L, Leibovici A. Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993; 150:1063-9.
52. Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am J Geriatr Psychiatry 1993;1:82-4.
53. Herrmann N, Eryavec G. Buspirone in the management of agitation and aggression associated with dementia. Am J Geriatr Psychiatry 1993;1:249-53.
54. Colenda C. Buspirone in treatment of agitated demented patient [letter]. Lancet 1988 May 21;1:1169.
55. Tiller JW, Dakis IA, Shaw IM. Short-term buspirone treatment in disinhibition with dementia [letter]. Lancet 1988 Aug 27;2:510.
56. Holzer JC, Gitelman DR, Price BH. Efficacy of buspirone in the treatment of dementia with aggression [letter]. Am J Psychiatry 1995;152:812.
57. Cantillon M, Brunswick R, Molina D, Bahro M. Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry 1996;4:263-7.
58. Davidson PW, Cain NN, Sloane-Reeves JE, Van Speybroech A, Segel J, Gutkin J, Quijano LE, Kramer BM, Porter B, Shoham I, et al. Characteristics of community-based individuals with mental retardation and aggressive behavioral disorders. Am J Ment Retard 1994;98:704-16.
59. Stanislav SW, Fabre T, Crismon ML, Childs A. Buspirone's efficacy in organic-induced aggression. J Clin Psychopharmacol 1994;14:126-30.
60. Hillbrand M. The use of buspirone with aggressive behavior [letter]. J Autism Dev Disord 1995;25:663-4.
61. Ricketts RW, Goza AB, Ellis CR, Singh YN, Chambers S, Singh NN, Cooke JC. Clinical effects of buspirone on intractable self-injury in adults with mental retardation. J Am Acad Child Adolesc Psychiatry 1994;33:270-6.
62. Gross MD. Buspirone in ADHD with ODD [letter] J Am Acad Child Adolesc Psychiatry 1995;34:1260.
63. Feighner JP, Cohen JB. Analysis of individual symptoms in generalized anxiety: a pooled, multi-study, double-blind evaluation of buspirone. Neuropsychobiology 1989;21:124-30.
64. Quaison N, Ward D, Kitchen T. Buspirone for aggression [letter]. J Am Acad Child Adolesc Psychiatry 1991;30:1026.
65. Balon R. Buspirone for attention deficit hyperactivity disorder [letter]. J Clin Psychopharmacol 1990;10:77.
66. McCormick LH, Rizzuto GT, Knuckles HB. A pilot study of buspirone in attention deficit hyperactivity disorder. Arch Fam Med 1994;3:68-70.
67. Fiore MC, Novotny TE, Pierce JP. Methods used to quit smoking in the United States: do cessation programs help? JAMA 1990;263: 2760-5.
68. Gawin F, Compton M, Byck R. Buspirone reduces smoking [letter]. Arch Gen Psychiatry 1989:46:288.
69. Hillemann DE, Mohiuddin SM, Del Core MG, Sketch MH. Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch Intern Med 1992;152:350-2.
70. Robinson MD, Pettice YL, Smith WA, Cederstrom EA, Sutherland DE, Davis H. Buspirone effect on tobacco withdrawal symptoms: a randomized placebo-controlled trial. J Am Board Fam Pract 1992;5:1-9.
71. West R, Hajek P, McNeill A. Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers clinic. Psychopharmacology (Berl) 1991;104:91-6.
72. Cinciripini PM, Lapitsky L, Seay S, Wallfisch A, Meyer WJ, Van Vunakis H. A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high-and low-anxiety smokers. J Clin Psychopharmacol 1995;15:182-91.
73. Schneider NG, Olmstead RE, Steinberg C, Sloan K, Daims RM, Brown HV. Efficacy of buspirone in smoking cessation: a placebo-controlled trial. Clin Pharmacol Ther 1996;60:568-75.